The legal action centers on accusations that GeneDx provided false and misleading information to the market throughout the defined class period. The claims gained momentum after the company’s Q1 2026 financial report, released on May 4, 2026, revealed significant fiscal setbacks. These included a decline in adjusted gross margins, reduced earnings projections, and a $31.3 million impairment charge tied to Fabric Genomics.
Investors Urged to Join GeneDx Securities Fraud Class Action
The Schall Law Firm is rallying investors to participate in a class action lawsuit against GeneDx Holdings Corp. following allegations of misleading financial disclosures. Shareholders who acquired securities between April 16, 2025, and May 4, 2026, have until August 3, 2026, to join the litigation regarding potential violations of federal securities laws.
Legal counsel argues that these disclosures exposed the inaccuracy of previous public statements, directly resulting in financial losses for shareholders. While the class has not yet received formal certification, the firm is currently organizing potential plaintiffs. Brian Schall, lead attorney at the Los Angeles-based firm, is overseeing the outreach to investors seeking to recover damages. Those who choose not to participate remain absent class members, meaning they are not currently represented by specific counsel in the ongoing proceedings.
Comments (0)
No comments yet. Be the first!